Supplementary Figure 4 from Tankyrase and the Canonical Wnt Pathway Protect Lung Cancer Cells from EGFR Inhibition

PDF file - 240K, Demonstration that CK1alpha or CK2alpha knockdown results in enhanced sensitivity of NSCLC cells to gefitinib treatment, that these knockdowns reduce the expression of the corresponding proteins, that treatment with the CK1� activator pyrvinium pamoate acts synergistically with gefitinib to eliminate NSCLC cells, and specificity of this synergistic cell killing for NSCLC cells following EGFR inhibition